Teachers Retirement System of The State of Kentucky purchased a new position in shares of Calithera Biosciences, Inc. (NASDAQ:CALA) during the first quarter, Holdings Channel reports. The institutional investor purchased 18,500 shares of the biotechnology company’s stock, valued at approximately $214,000.

Several other hedge funds have also modified their holdings of the stock. Wellington Management Group LLP acquired a new stake in shares of Calithera Biosciences during the first quarter worth approximately $47,550,000. FMR LLC increased its stake in shares of Calithera Biosciences by 278.2% in the first quarter. FMR LLC now owns 1,462,190 shares of the biotechnology company’s stock worth $16,888,000 after buying an additional 1,075,592 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Calithera Biosciences by 99.8% in the first quarter. Vanguard Group Inc. now owns 925,015 shares of the biotechnology company’s stock worth $10,684,000 after buying an additional 462,137 shares during the last quarter. RA Capital Management LLC acquired a new stake in shares of Calithera Biosciences during the first quarter worth approximately $8,374,000. Finally, Bogle Investment Management L P DE acquired a new stake in shares of Calithera Biosciences during the first quarter worth approximately $5,732,000. 54.51% of the stock is owned by institutional investors.

Calithera Biosciences, Inc. (NASDAQ CALA) traded up 15.35% during mid-day trading on Friday, reaching $13.90. The company’s stock had a trading volume of 1,034,907 shares. The company has a 50-day moving average price of $15.88 and a 200-day moving average price of $12.74. Calithera Biosciences, Inc. has a 12-month low of $2.20 and a 12-month high of $20.05. The firm’s market cap is $493.12 million.

Calithera Biosciences (NASDAQ:CALA) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.15) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.14. The business had revenue of $7.26 million during the quarter, compared to the consensus estimate of $4.80 million. On average, equities research analysts expect that Calithera Biosciences, Inc. will post ($0.83) earnings per share for the current year.

WARNING: This news story was first reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/teachers-retirement-system-of-the-state-of-kentucky-purchases-new-position-in-calithera-biosciences-inc-nasdaqcala/1479398.html.

A number of research firms have issued reports on CALA. BidaskClub raised Calithera Biosciences from a “hold” rating to a “buy” rating in a research report on Friday, July 7th. Zacks Investment Research downgraded Calithera Biosciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 13th. Wells Fargo & Company reissued an “outperform” rating and issued a $20.00 target price (up from $15.00) on shares of Calithera Biosciences in a research report on Tuesday, June 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $19.00 target price (up from $14.00) on shares of Calithera Biosciences in a research report on Monday, June 12th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $15.50.

In related news, VP Keith Orford sold 2,120 shares of the stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $18.31, for a total value of $38,817.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last ninety days, insiders sold 3,470 shares of company stock valued at $61,817. 16.30% of the stock is owned by insiders.

About Calithera Biosciences

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Want to see what other hedge funds are holding CALA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Calithera Biosciences, Inc. (NASDAQ:CALA).

Institutional Ownership by Quarter for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.